ENTRADA THERAPEUTICS, INC. Depreciation
ENTRADA THERAPEUTICS, INC. (TRDA) reported Depreciation of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. depreciation for the quarter ending 2026-06-30 was $800.00K, a 27.27% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. depreciation for the quarter ending 2026-03-31 was $805.00K, a 14.90% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $886.00K, a 10.69% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $1.20M, a 33.33% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. depreciation for fiscal 2025 was $4.10M, a 8.56% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. depreciation for fiscal 2024 was $3.77M, a 32.81% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. depreciation for fiscal 2023 was $2.84M, a 49.92% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. depreciation for fiscal 2022 was $1.90M, a 69.65% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-05 | $1.65M 10-Q · filed 2026-08-05 | $2.49M derived: sum of 3 quarters · filed 2026-08-05 | $3.69M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $805.00K 10-Q · filed 2026-05-07 | $1.69M derived: sum of 2 quarters · filed 2026-05-07 | $2.89M derived: sum of 3 quarters · filed 2026-05-07 | $3.99M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $886.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.09M derived: sum of 2 quarters · filed 2026-02-26 | $3.19M derived: sum of 3 quarters · filed 2026-08-05 | $4.10M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.30M derived: sum of 2 quarters · filed 2026-08-05 | $3.21M 10-Q · filed 2025-11-06 | $4.24M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $1.10M 10-Q · filed 2026-08-05 | $1.98M 10-Q · filed 2026-08-05 | $3.04M derived: sum of 3 quarters · filed 2026-08-05 | $3.94M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $946.00K 10-Q · filed 2026-05-07 | $1.94M derived: sum of 2 quarters · filed 2026-05-07 | $2.84M derived: sum of 3 quarters · filed 2026-05-07 | $3.74M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.89M derived: sum of 2 quarters · filed 2026-02-26 | $2.79M derived: sum of 3 quarters · filed 2026-02-26 | $3.77M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-06 | $1.80M derived: sum of 2 quarters · filed 2025-11-06 | $2.78M 10-Q · filed 2025-11-06 | $3.47M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $900.00K 10-Q · filed 2025-08-06 | $1.84M 10-Q · filed 2025-08-06 | $2.57M derived: sum of 3 quarters · filed 2025-08-06 | $3.37M derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $934.00K 10-Q · filed 2025-05-08 | $1.67M derived: sum of 2 quarters · filed 2025-05-08 | $2.47M derived: sum of 3 quarters · filed 2025-05-08 | $3.17M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.54M derived: sum of 2 quarters · filed 2025-02-27 | $2.24M derived: sum of 3 quarters · filed 2025-02-27 | $2.84M 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $800.00K 10-Q · filed 2024-11-05 | $1.50M derived: sum of 2 quarters · filed 2024-11-05 | $2.10M 10-Q · filed 2024-11-05 | $2.57M derived: sum of 4 quarters · filed 2024-11-05 | ||
| 2023-06-30 | $700.00K 10-Q · filed 2024-08-13 | $1.27M 10-Q · filed 2024-08-13 | $1.77M derived: sum of 3 quarters · filed 2024-08-13 | $2.27M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $541.00K 10-Q · filed 2024-05-07 | $1.07M derived: sum of 2 quarters · filed 2024-05-07 | $1.57M derived: sum of 3 quarters · filed 2024-05-07 | $2.07M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.03M derived: sum of 2 quarters · filed 2024-03-13 | $1.53M derived: sum of 3 quarters · filed 2024-03-13 | $1.90M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-07 | $1.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.37M 10-Q · filed 2023-11-07 | $1.37M 10-Q · filed 2022-11-07 | $1.75M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-08 | $853.00K 10-Q · filed 2023-08-08 | $856.00K 10-Q · filed 2022-08-11 | $1.25M derived: sum of 3 quarters · filed 2023-08-08 | $1.55M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $390.00K 10-Q · filed 2023-05-10 | $754.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.05M derived: sum of 3 quarters · filed 2023-05-10 | $1.35M derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $664.00K derived: sum of 2 quarters · filed 2023-03-06 | $964.00K derived: sum of 3 quarters · filed 2023-03-06 | $1.12M 10-K · filed 2023-03-06 | ||
| 2021-09-30 | $300.00K 10-Q · filed 2022-11-07 | $600.00K derived: sum of 2 quarters · filed 2022-11-07 | $753.00K 10-Q · filed 2022-11-07 | $897.00K derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-11 | $451.00K 10-Q · filed 2022-08-11 | $597.00K derived: sum of 3 quarters · filed 2022-08-11 | $697.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $199.00K 10-Q · filed 2022-05-12 | $297.00K derived: sum of 2 quarters · filed 2022-05-12 | $397.00K derived: sum of 3 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $198.00K derived: sum of 2 quarters · filed 2022-03-15 | $326.00K 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $100.00K 10-Q · filed 2021-12-09 | $228.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |